NL1008139C2 - Antimicrobiële peptiden. - Google Patents

Antimicrobiële peptiden. Download PDF

Info

Publication number: NL1008139C2
Authority: NL; Netherlands
Prior art keywords: amino acids; peptide; peptides according; domain; amino acid
Prior art date: 1998-01-27

Application number

NL1008139A

Other languages

English (en)

Dutch (nl)

Inventor

Arie Van Nieuw Amerongen

Engelmundus Cornelis I Veerman

Willem Van T Hof

Eva Johanna Helmerhorst

Original Assignee

Stichting Tech Wetenschapp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-27

Filing date

1998-01-27

Publication date

1999-07-28

1998-01-27 Priority to NL1008139A priority Critical patent/NL1008139C2/nl

1998-01-27 Application filed by Stichting Tech Wetenschapp filed Critical Stichting Tech Wetenschapp

1999-01-26 Priority to EP99902926A priority patent/EP1051433B1/fr

1999-01-26 Priority to AU23014/99A priority patent/AU759026B2/en

1999-01-26 Priority to ES99902926T priority patent/ES2229669T3/es

1999-01-26 Priority to PCT/NL1999/000045 priority patent/WO1999037678A2/fr

1999-01-26 Priority to DE69920877T priority patent/DE69920877T2/de

1999-01-26 Priority to CA002319094A priority patent/CA2319094C/fr

1999-01-26 Priority to US09/601,124 priority patent/US6638531B1/en

1999-01-26 Priority to AT99902926T priority patent/ATE278710T1/de

1999-01-26 Priority to JP2000528598A priority patent/JP2003524578A/ja

1999-07-28 Application granted granted Critical

1999-07-28 Publication of NL1008139C2 publication Critical patent/NL1008139C2/nl

Links

102000044503 Antimicrobial Peptides Human genes 0.000 title description 3
108700042778 Antimicrobial Peptides Proteins 0.000 title description 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 171
150000001413 amino acids Chemical class 0.000 claims abstract description 99
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 77
230000000845 anti-microbial effect Effects 0.000 claims abstract description 7
229940024606 amino acid Drugs 0.000 claims description 80
235000001014 amino acid Nutrition 0.000 claims description 80
150000001408 amides Chemical class 0.000 claims description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
239000003242 anti bacterial agent Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
239000004472 Lysine Substances 0.000 claims description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
239000003429 antifungal agent Substances 0.000 claims description 7
206010017533 Fungal infection Diseases 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 5
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
210000004899 c-terminal region Anatomy 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229960003104 ornithine Drugs 0.000 claims description 5
VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 claims description 4
239000004475 Arginine Substances 0.000 claims description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
239000004473 Threonine Substances 0.000 claims description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
235000004279 alanine Nutrition 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
229940121375 antifungal agent Drugs 0.000 claims description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
235000009582 asparagine Nutrition 0.000 claims description 4
229960001230 asparagine Drugs 0.000 claims description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
229960000310 isoleucine Drugs 0.000 claims description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
229930182817 methionine Natural products 0.000 claims description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
239000004474 valine Substances 0.000 claims description 4
208000035143 Bacterial infection Diseases 0.000 claims description 2
208000031888 Mycoses Diseases 0.000 claims description 2
125000003158 alcohol group Chemical group 0.000 claims description 2
150000001299 aldehydes Chemical class 0.000 claims description 2
208000022362 bacterial infectious disease Diseases 0.000 claims description 2
125000002843 carboxylic acid group Chemical group 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
241000894006 Bacteria Species 0.000 description 11
230000002209 hydrophobic effect Effects 0.000 description 11
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
241000222122 Candida albicans Species 0.000 description 9
101000898505 Homo sapiens Histatin-3 Proteins 0.000 description 9
239000000872 buffer Substances 0.000 description 9
KSXBMTJGDUPBBN-VPKNIDFUSA-N histatin 5 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 KSXBMTJGDUPBBN-VPKNIDFUSA-N 0.000 description 9
239000013641 positive control Substances 0.000 description 9
102400000777 His3-(20-43)-peptide Human genes 0.000 description 8
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
229940095731 candida albicans Drugs 0.000 description 6
229960003260 chlorhexidine Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
241000194019 Streptococcus mutans Species 0.000 description 5
241000194023 Streptococcus sanguinis Species 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000004310 lactic acid Substances 0.000 description 5
235000014655 lactic acid Nutrition 0.000 description 5
-1 m-maleimidobenzoyl Chemical group 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000008057 potassium phosphate buffer Substances 0.000 description 5
230000035899 viability Effects 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
241000194024 Streptococcus salivarius Species 0.000 description 4
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
230000001332 colony forming effect Effects 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
241000222120 Candida <Saccharomycetales> Species 0.000 description 3
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
241000222126 [Candida] glabrata Species 0.000 description 3
229960003942 amphotericin b Drugs 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000006161 blood agar Substances 0.000 description 3
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
241000186046 Actinomyces Species 0.000 description 2
241000186045 Actinomyces naeslundii Species 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
241000222173 Candida parapsilosis Species 0.000 description 2
241000233866 Fungi Species 0.000 description 2
241000605986 Fusobacterium nucleatum Species 0.000 description 2
108010019494 Histatins Proteins 0.000 description 2
102000006492 Histatins Human genes 0.000 description 2
241000588748 Klebsiella Species 0.000 description 2
241000218588 Lactobacillus rhamnosus Species 0.000 description 2
101800004819 PGLa Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
241000605861 Prevotella Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
241001148135 Veillonella parvula Species 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000009343 monoculture Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
238000007747 plating Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229920003002 synthetic resin Polymers 0.000 description 2
239000000057 synthetic resin Substances 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
VYMHBQQZUYHXSS-UHFFFAOYSA-N 2-(3h-dithiol-3-yl)pyridine Chemical compound C1=CSSC1C1=CC=CC=N1 VYMHBQQZUYHXSS-UHFFFAOYSA-N 0.000 description 1
MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000605909 Fusobacterium Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 1
102000003752 Lipocalin 1 Human genes 0.000 description 1
108010057281 Lipocalin 1 Proteins 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
240000000968 Parkia biglobosa Species 0.000 description 1
241000235645 Pichia kudriavzevii Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241001135221 Prevotella intermedia Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
102000018968 Salivary Cystatins Human genes 0.000 description 1
108010026774 Salivary Cystatins Proteins 0.000 description 1
102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
241000607447 Yersinia enterocolitica Species 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001857 anti-mycotic effect Effects 0.000 description 1
230000000656 anti-yeast Effects 0.000 description 1
238000011482 antibacterial activity assay Methods 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
208000032343 candida glabrata infection Diseases 0.000 description 1
229940055022 candida parapsilosis Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
108010005636 polypeptide C Proteins 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000001974 tryptic soy broth Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940098232 yersinia enterocolitica Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)

NL1008139A 1998-01-27 1998-01-27 Antimicrobiële peptiden. NL1008139C2 (nl)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
NL1008139A NL1008139C2 (nl)	1998-01-27	1998-01-27	Antimicrobiële peptiden.
AU23014/99A AU759026B2 (en)	1998-01-27	1999-01-26	Antimicrobial peptides
ES99902926T ES2229669T3 (es)	1998-01-27	1999-01-26	Peptidos antimicrobianos.
PCT/NL1999/000045 WO1999037678A2 (fr)	1998-01-27	1999-01-26	Peptides antimicrobiens
EP99902926A EP1051433B1 (fr)	1998-01-27	1999-01-26	Peptides antimicrobiens
DE69920877T DE69920877T2 (de)	1998-01-27	1999-01-26	Antimikrobiell wirksame peptide
CA002319094A CA2319094C (fr)	1998-01-27	1999-01-26	Peptides antimicrobiens
US09/601,124 US6638531B1 (en)	1998-01-27	1999-01-26	Antimicrobial peptides
AT99902926T ATE278710T1 (de)	1998-01-27	1999-01-26	Antimikrobiell wirksame peptide
JP2000528598A JP2003524578A (ja)	1998-01-27	1999-01-26	抗微生物性ペプチド

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL1008139A NL1008139C2 (nl)	1998-01-27	1998-01-27	Antimicrobiële peptiden.
NL1008139		1998-01-27

Publications (1)

Publication Number	Publication Date
NL1008139C2 true NL1008139C2 (nl)	1999-07-28

Family

ID=19766423

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL1008139A NL1008139C2 (nl)	1998-01-27	1998-01-27	Antimicrobiële peptiden.

Country Status (10)

Country	Link
US (1)	US6638531B1 (fr)
EP (1)	EP1051433B1 (fr)
JP (1)	JP2003524578A (fr)
AT (1)	ATE278710T1 (fr)
AU (1)	AU759026B2 (fr)
CA (1)	CA2319094C (fr)
DE (1)	DE69920877T2 (fr)
ES (1)	ES2229669T3 (fr)
NL (1)	NL1008139C2 (fr)
WO (1)	WO1999037678A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002519155A (ja) *	1998-07-02	2002-07-02	スティヒティング・スケルトル・ティシュー・エンジニアリング・グループ・アムステルダム	抗微生物性ペプチドを有する骨セメント
NL1010692C2 (nl) *	1998-12-01	2000-06-06	Stichting Tech Wetenschapp	Antivirale peptiden.
EP1174027A1 (fr) *	2000-07-17	2002-01-23	HOM Consultancy B.V.	Utilisations de peptides antimicrobiens
US7550558B2 (en) *	2001-06-01	2009-06-23	Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp)	Antimicrobial peptides and methods for identifying and using such peptides
US7550430B2 (en) *	2003-08-18	2009-06-23	E.I. Du Pont De Nemours And Company	Cationic antimicrobial peptides and compositions
JP2005350424A (ja) *	2004-06-14	2005-12-22	Kyocera Chemical Corp	固形製剤および固形製剤の製造方法
EP3384938A1 (fr)	2011-09-12	2018-10-10	Moderna Therapeutics, Inc.	Acides nucléiques techniques et leurs procédés d'utilisation
EP3520821A1 (fr)	2012-04-02	2019-08-07	Moderna Therapeutics, Inc.	Polynucléotides modifiés pour la production d'agents biologiques et de protéines associées à une maladie humaine
CN108949772A (zh)	2012-04-02	2018-12-07	现代泰克斯公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US8963676B1 (en) *	2013-03-12	2015-02-24	XP Power Limited	Configurable transformer module
US9556226B2 (en)	2013-03-15	2017-01-31	The Board Of Trustees Of The University Of Arkansas	Peptides with antifungal activity and methods of using the peptides
US10457709B2 (en)	2015-06-30	2019-10-29	Chain Antimicrobials Oy	Antimicrobial peptides, their variants and uses
EP3423478B1 (fr)	2015-06-30	2020-05-27	Chain Antimicrobials OY	Nouveaux peptides antimicrobiens, leurs variants et leurs utilisations
CN107849103B (zh)	2015-06-30	2021-11-09	链状抗菌剂公司	新抗微生物肽、它们的变体和用途
ES2981535T3 (es)	2015-11-10	2024-10-09	Visterra Inc	Conjugados de molécula de anticuerpo-fármaco que se unen específicamente al lipopolisacárido y usos de los mismos
JP6658265B2 (ja) *	2016-04-26	2020-03-04	ライオン株式会社	インビトロバイオフィルムモデルの製造方法、ならびに評価方法及び口腔用組成物を選定する方法
ES2994374T3 (en)	2017-01-18	2025-01-23	Visterra Inc	Antibody molecule-drug conjugates and uses thereof
WO2019139891A1 (fr)	2018-01-09	2019-07-18	Synthetic Biologics, Inc.	Agents de phosphatase alcaline pour le traitement de troubles neurodéveloppementaux
US11638699B2 (en)	2018-03-20	2023-05-02	Theriva Biologics, Inc.	Intestinal alkaline phosphatase formulations
US11654184B2 (en)	2018-03-20	2023-05-23	Theriva Biologics, Inc.	Alkaline phosphatase agents for treatment of radiation disorders
WO2020227263A1 (fr)	2019-05-06	2020-11-12	Synthetic Biologics, Inc.	Traitements oncologiques à base de phosphate alcalin
EP4126064A1 (fr)	2020-04-03	2023-02-08	Visterra, Inc.	Conjugués molécule d'anticorps-médicament et leurs utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991012815A1 (fr) *	1990-02-23	1991-09-05	Bristol-Myers Squibb Company	COMPOSITIONS ET PROCEDES POUR TRAITER DES INFECTIONS CAUSEES PAR DES ORGANISMES SENSIBLES AUX ANTIBIOTIQUES β-LACTAME
WO1992001462A1 (fr) *	1990-07-19	1992-02-06	The Scripps Research Institute	Compositions de peptides amphiphiles et analogues de ces compositions
WO1993024138A1 (fr) *	1992-06-01	1993-12-09	Magainin Pharmaceuticals, Inc.	Peptides biologiquement actifs presentant des substitutions n-terminales
WO1996008270A2 (fr) *	1994-09-13	1996-03-21	Magainin Pharmaceuticals Inc.	Procede permettant d'inhiber la transmission de maladies sexuellement transmissibles a l'aide d'antimicrobiens du type magainin ou de composes de squalamine
WO1996040251A1 (fr) *	1995-06-07	1996-12-19	Ophidian Pharmaceuticals, Inc.	Prevention et traitement de la septicemie

1998
- 1998-01-27 NL NL1008139A patent/NL1008139C2/nl not_active IP Right Cessation
1999
- 1999-01-26 EP EP99902926A patent/EP1051433B1/fr not_active Expired - Lifetime
- 1999-01-26 AU AU23014/99A patent/AU759026B2/en not_active Ceased
- 1999-01-26 DE DE69920877T patent/DE69920877T2/de not_active Expired - Fee Related
- 1999-01-26 AT AT99902926T patent/ATE278710T1/de not_active IP Right Cessation
- 1999-01-26 ES ES99902926T patent/ES2229669T3/es not_active Expired - Lifetime
- 1999-01-26 JP JP2000528598A patent/JP2003524578A/ja active Pending
- 1999-01-26 CA CA002319094A patent/CA2319094C/fr not_active Expired - Fee Related
- 1999-01-26 WO PCT/NL1999/000045 patent/WO1999037678A2/fr not_active Ceased
- 1999-01-26 US US09/601,124 patent/US6638531B1/en not_active Expired - Fee Related

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991012815A1 (fr) *	1990-02-23	1991-09-05	Bristol-Myers Squibb Company	COMPOSITIONS ET PROCEDES POUR TRAITER DES INFECTIONS CAUSEES PAR DES ORGANISMES SENSIBLES AUX ANTIBIOTIQUES β-LACTAME
WO1992001462A1 (fr) *	1990-07-19	1992-02-06	The Scripps Research Institute	Compositions de peptides amphiphiles et analogues de ces compositions
WO1993024138A1 (fr) *	1992-06-01	1993-12-09	Magainin Pharmaceuticals, Inc.	Peptides biologiquement actifs presentant des substitutions n-terminales
WO1996008270A2 (fr) *	1994-09-13	1996-03-21	Magainin Pharmaceuticals Inc.	Procede permettant d'inhiber la transmission de maladies sexuellement transmissibles a l'aide d'antimicrobiens du type magainin ou de composes de squalamine
WO1996040251A1 (fr) *	1995-06-07	1996-12-19	Ophidian Pharmaceuticals, Inc.	Prevention et traitement de la septicemie

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AOYAGI H ET AL: "SYNTHESIS OF ANTIBACTERIAL PEPTIDES, GRAMICIDIN S ANALOGS AND DESIGNED AMPHIPHILIC OLIGOPEPTIDES", TETRAHEDRON, vol. 44, no. 3, 1 January 1988 (1988-01-01), pages 877 - 886, XP000574054 *
CHEMICAL ABSTRACTS, vol. 103, no. 19, 11 November 1985, Columbus, Ohio, US; abstract no. 160837, SASAKI, TOORU ET AL: "Syntheses and properties of H-[Orn-Leu]n-OH (n = 1-12) and cyclo[Orn-Leu-]n (n = 2-8)" XP002083173 *
CHEMICAL ABSTRACTS, vol. 106, no. 25, 22 June 1987, Columbus, Ohio, US; abstract no. 214352, MIHARA, HISAKAZU ET AL: "Design and synthesis of basic amphiphilic peptides possessing antimicrobial activity and their interaction with lipids" XP002083172 *
MIHARA, HISAKAZU ET AL: "Design and synthesis of amphiphilic basic peptides with antibacterial activity and their interaction with model membrane", BULL. CHEM. SOC. JPN. (1987), 60(2), 697-706 CODEN: BCSJA8;ISSN: 0009-2673, 1987, XP002083171 *
PEPT. CHEM. (1985), VOLUME DATE 1984, 22ND, 361-6 CODEN: PECHDP;ISSN: 0388-3698, 1985 *
PEPT. CHEM. (1986), VOLUME DATE 1985, 23RD, 223-8 CODEN: PECHDP;ISSN: 0388-3698, 1986 *
TAKAHASHI, SHO ET AL: "Synthesis of.alpha.-helices having a positively charged random coil-block on either N- or C-terminal", BULL. CHEM. SOC. JPN. (1988), 61(7), 2467-71 CODEN: BCSJA8;ISSN: 0009-2673, 1988, XP002083167 *
TOSSI, ALESSANDRO ET AL: "Identification and characterization of a primary antibacterial domain in CAP18, a lipopolysaccharide binding protein from rabbit leukocytes", FEBS LETT. (1994), 339(1-2), 108-12 CODEN: FEBLAL;ISSN: 0014-5793, 1994, XP002083170 *

Also Published As

Publication number	Publication date
WO1999037678A3 (fr)	1999-10-14
ES2229669T3 (es)	2005-04-16
ATE278710T1 (de)	2004-10-15
CA2319094A1 (fr)	1999-07-29
EP1051433A2 (fr)	2000-11-15
EP1051433B1 (fr)	2004-10-06
WO1999037678A2 (fr)	1999-07-29
AU759026B2 (en)	2003-04-03
AU2301499A (en)	1999-08-09
CA2319094C (fr)	2009-03-17
JP2003524578A (ja)	2003-08-19
DE69920877T2 (de)	2005-02-03
US6638531B1 (en)	2003-10-28
DE69920877D1 (de)	2004-11-11

Publication	Publication Date	Title
NL1008139C2 (nl)	1999-07-28	Antimicrobiële peptiden.
US8680058B2 (en)	2014-03-25	Selectively targeted antimicrobial peptides and the use thereof
US7723468B2 (en)	2010-05-25	Antimicrobial peptide, compositions, and uses therefor
CN114269771B (zh)	2024-11-29	Romo1来源抗微生物肽及其变体
DE102007036128A1 (de)	2009-02-12	Antibiotische Peptide
US10174081B2 (en)	2019-01-08	Antimicrobial peptides and uses therefore
KR101896927B1 (ko)	2018-09-12	흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물
Zhang et al.	2016	Pleurocidin congeners demonstrate activity against Streptococcus and low toxicity on gingival fibroblasts
JP2003524578A5 (fr)	2006-02-02
US5885965A (en)	1999-03-23	Anti-fungal D-amino acid histatin-based peptides
EP2750689B1 (fr)	2019-08-21	Dérivés d'apidaecine utilisés comme peptides antibiotiques
US7348402B2 (en)	2008-03-25	Antimicrobial peptide, its analogs and antimicrobial composition comprising them
SE2151338A1 (en)	2023-04-30	Truncated peptides
KR20180117793A (ko)	2018-10-30	왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물
CA2491011A1 (fr)	2004-01-15	Peptides lineaires cationiques ayant des proprietes antibacteriennes et/ou antifongiques
US10150795B2 (en)	2018-12-11	Peptide having antimicrobial activity against pathogens and antimicrobial peptide composition comprising the same
US5969098A (en)	1999-10-19	Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use
JP3488133B2 (ja)	2004-01-19	抗菌性ペプチド
IT202100029738A1 (it)	2023-05-24	Peptide ad attività antimicotica e antibatterica
US20090149391A1 (en)	2009-06-11	Novel antimicrobial bolisin peptides
WO2013064633A1 (fr)	2013-05-10	Dérivés du peptide oncopeltus en tant que peptides antimicrobiens
DE10160170A1 (de)	2003-07-17	Neue antimikrobielle Bolisinpeptide

Legal Events

Date	Code	Title	Description
2001-12-03	SD	Assignments of patents	Owner name: AM-PHARMA B.V.
2004-10-01	VD1	Lapsed due to non-payment of the annual fee	Effective date: 20040801